New hope for tough leukemia: drug combo trial targets older and relapsed patients
NCT ID NCT03319901
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug venetoclax to standard chemotherapy can help treat acute lymphoblastic leukemia (ALL). It includes older adults (60+) with newly diagnosed ALL and adults (18+) whose leukemia has come back or not responded to treatment. The goal is to find the safest dose and see how well the combination works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Intermountain LDS Hospital
Salt Lake City, Utah, 84143, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor's DNA guide better cancer care for kids?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can donor immune cells tame stem cell transplant risks?
- A guided path back to work after blood cancer: a trial tests the impact